NFKB1 and neoplasm: To inveterate the tumor progression inhibitory effect of regorafenib was through the modulation of p38 MAPK‐ and ERK‐mediated NF‐κB signaling, we performed with Western blot for tumor progression related proteins evaluation by treated cells with p38 MAPK and ERK inhibitors.